Eight patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2038. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2038
Next term end
7
Patent families
When these terms end
Each bar runs from grant to computed term end. 2023 to 2043.20272031203520392043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
20 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2039 · High confidence
Also notable
Ends May 2039 · High confidence
Also notable
Ends Aug 2043 · High confidence
WNT Surrogate Molecules and Uses Thereof
US 11,773,171
The most cited patent in this portfolio, cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2039.
ANTI-LRP5/6 Antibodies and Methods of Use
US 11,746,150
Cited by 7 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2039.
Monospecific Anti-Frizzled Antibodies and Methods of Use
US 12,606,629
Granted 2026. Too new for citation comparison; protection runs to 2043.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 5, 2027The maintenance fee for ANTI-LRP5/6 Antibodies and Methods of Use (US 11,746,150) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 1 fee due Apr 3, 2027The maintenance fee for WNT Surrogate Molecules and Uses Thereof (US 11,773,171) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Tissue-Specific WNT Signal Enhancing Molecules and Uses Thereof (US 11,958,891) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| WNT Surrogate Molecules and Uses Thereof | 2 in force | to Jul 2039 |
| Monospecific Anti-Frizzled Antibodies and Methods of Use | 1 in force | to Aug 2043 |
| Tissue-Specific WNT Signal Enhancing Molecules and Uses | 1 in force | to Feb 2043 |
| Liver-Specific WNT Signal Enhancing Molecules and Uses Thereof | 1 in force | to Nov 2041 |
| ANTI-LRP5/6 Antibodies and Methods of Use | 1 in force | to May 2039 |
Patents held now
Soonest term end first.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,006,368 | Anti-Frizzled Antibodies and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 12,297,278 | WNT Surrogate Molecules and Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 11,958,891 | Tissue-Specific WNT Signal Enhancing Molecules and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,746,150 | ANTI-LRP5/6 Antibodies and Methods of Use In force · High confidence | In force | High confidence | |
| US 11,773,171 | WNT Surrogate Molecules and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,240,876 | Liver-Specific WNT Signal Enhancing Molecules and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,466,884 | Tissue-Specific WNT Signal Enhancing Molecules and Uses In force · High confidence | In force | High confidence | |
| US 12,606,629 | Monospecific Anti-Frizzled Antibodies and Methods of Use In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 20 applications pending · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.